2-168927218-C-T
Variant summary
Our verdict is Benign. Variant got -18 ACMG points: 2P and 20B. PM1BP4_StrongBP6_Very_StrongBS1BS2
The NM_003742.4(ABCB11):c.3556G>A(p.Glu1186Lys) variant causes a missense change. The variant allele was found at a frequency of 0.0016 in 1,613,880 control chromosomes in the GnomAD database, including 40 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign,other (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. E1186G) has been classified as Uncertain significance.
Frequency
Consequence
NM_003742.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
ABCB11 | NM_003742.4 | c.3556G>A | p.Glu1186Lys | missense_variant | 26/28 | ENST00000650372.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
ABCB11 | ENST00000650372.1 | c.3556G>A | p.Glu1186Lys | missense_variant | 26/28 | NM_003742.4 | P1 | ||
ABCB11 | ENST00000649448.1 | c.1933G>A | p.Glu645Lys | missense_variant | 13/15 | ||||
ABCB11 | ENST00000648875.1 | c.19G>A | p.Glu7Lys | missense_variant | 1/3 | ||||
ABCB11 | ENST00000439188.1 | c.*1954G>A | 3_prime_UTR_variant, NMD_transcript_variant | 13/15 | 2 |
Frequencies
GnomAD3 genomes AF: 0.00871 AC: 1325AN: 152158Hom.: 24 Cov.: 32
GnomAD3 exomes AF: 0.00211 AC: 525AN: 249196Hom.: 4 AF XY: 0.00157 AC XY: 212AN XY: 135192
GnomAD4 exome AF: 0.000856 AC: 1251AN: 1461604Hom.: 16 Cov.: 31 AF XY: 0.000715 AC XY: 520AN XY: 727084
GnomAD4 genome AF: 0.00872 AC: 1328AN: 152276Hom.: 24 Cov.: 32 AF XY: 0.00807 AC XY: 601AN XY: 74460
ClinVar
Submissions by phenotype
not provided Benign:3Other:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
other, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | May 02, 2018 | - Variant classified as "other reportable" ??? variant is clinically benign (not associated with disease) but is reported when observed (e.g. pseudodeficiency alleles). |
Benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Dec 01, 2023 | ABCB11: BS1, BS2 - |
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
not specified Benign:3
Benign, criteria provided, single submitter | clinical testing | GeneDx | Jul 12, 2016 | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. - |
Benign, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | - | - - |
Benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 18, 2022 | Variant summary: ABCB11 c.3556G>A (p.Glu1186Lys) results in a conservative amino acid change located in the ABC transporter-like, ATP-binding domain of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0021 in 249196 control chromosomes, predominantly at a frequency of 0.031 within the African or African-American subpopulation in the gnomAD database, including 4 homozygotes. The observed variant frequency within African or African-American control individuals in the gnomAD database is approximately 13.86 fold of the estimated maximal expected allele frequency for a pathogenic variant in ABCB11 causing Familial Intrahepatic Cholestasis phenotype (0.0022), strongly suggesting that the variant is a benign polymorphism found primarily in populations of African or African-American origin. Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as benign. Based on the evidence outlined above, the variant was classified as benign. - |
Progressive familial intrahepatic cholestasis type 2 Benign:2
Benign, no assertion criteria provided | clinical testing | Natera, Inc. | Jun 06, 2020 | - - |
Benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 28, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to rule this variant out of causing disease. Therefore, this variant is classified as benign. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at